Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells

Biochemical and Biophysical Research Communications

Volumn 434, Issue 1, 2013, Pages 95-101

  Qiao, Zhixin ^a,b   Ren, Suping ^a   Li, Weijing ^a   Wang, Xuanlin ^a   He, Min ^a   Guo, Yingjie ^b   Sun, Liwei ^c   He, Yuezhong ^a   Ge, Yubin ^b,d   Yu, Qun ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b JILIN UNIVERSITY   (China)

^c BEIHUA UNIVERSITY   (China)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Chidamide; DNA damage; Gemcitabine; Pancreatic cancer

Indexed keywords

CHECKPOINT KINASE 1; CHIDAMIDE; CS 055; GEMCITABINE; HBI 8000; HISTONE DEACETYLASE INHIBITOR; PROTEIN MCL 1; PROTEIN P21; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DOUBLE STRANDED DNA BREAK; DRUG POTENTIATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RECEPTOR DOWN REGULATION; S PHASE CELL CYCLE CHECKPOINT;

AMINOPYRIDINES; ANTIMETABOLITES, ANTINEOPLASTIC; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; PANCREATIC NEOPLASMS; UP-REGULATION;

EID: 84876807758     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.03.059     Document Type: Article

References (24)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA-A Cancer Journal for Clinicians 2012, 62(2012):10-29.
2. Shaib Y.H., Davila J.A., El-Serag B. The epidemiology of pancreatic cancer in the United States: changes below the surface. Alimentary Pharmacology & Therapeutics 2006, 24:87-94.
3. Rosenberg L. Pancreatic cancer - A review of emerging therapies. Drugs 2000, 59:1071-1089.
4. Dickinson M., Johnstone R.W., Prince H.M. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Investigational New Drugs 2010, 28:S3-S20.
5. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. Journal of Clinical Oncology 2009, 27:5459-5468.
6. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery 2006, 5:769-784.
7. Gallinari P., Di Marco S., Jones P., Pallaoro M., Steinkuhler C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Research 2007, 17:195-211.
8. Liu T., Kuljaca S., Tee A., Marshall G.M. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treatment Reviews 2006, 32:157-165.
9. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Letters 2008, 269:7-17.
10. Xie C., Edwards H., Xu X., Zhou H., Buck S.A., Stout M.L., Yu Q., Rubnitz J.E., Matherly L.H., Taub J.W., Ge Y. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clinical Cancer Research 2010, 16:5499-5510.
11. Gahr S., Ocker M., Ganslmayer M., Zopf S., Okamoto K., Hartl A., Leitner S., Hahn E.G., Herold C. The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. International Journal of Oncology 2007, 31:567-576.
12. Donadelli M., Costanzo C., Beghelli S., Scupoli M.T., Dandrea M., Bonora A., Piacentini P., Budillon A., Caraglia M., Scarpa A., Palmieri M. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochimica Et Biophysica Acta-Molecular Cell Research 2007, 1773:1095-1106.
13. Arnold N.B., Arkus N., Gunn J., Korc M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clinical Cancer Research 2007, 13:18-26.
14. Sung V., Richard N., Brady H., Maier A., Kelter G., Heise C. Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells. Cancer Science 2011, 102:1201-1207.
15. Gong K., Xie J., Yi H., Li W. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1-arrest,ROS-dependent apoptosis and differentiation in human leukemia cells. Biochemical Journal 2012.
16. Ning Z.-Q., Li Z.-B., Newman M.J., Shan S., Wang X.-H., Pan D.-S., Zhang J., Dong M., Du X., Lu X.-P. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemotherapy and Pharmacol 2011.
17. Liu L., Chen B., Qin S., Li S., He X., Qiu S., Zhao W., Zhao H. A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochemical and Biophysical Research Communications 2010, 392:190-195.
18. Xie C., Edwards H., Lograsso S.B., Buck S.A., Matherly L.H., Taub J.W., Ge Y. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatric Blood & Cancer 2012, 59:1245-1251.
19. Xu X., Xie C., Edwards H., Zhou H., Buck S.A., Ge Y. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PLoS ONE 2011, 6:e17138.
20. Yan C., Huang D., Zhang Y. The involvement of ROS overproduction and mitochondrial dysfunction in PBDE-47-induced apoptosis on Jurkat cells. Experimental and Toxicologic Pathology 2011, 63:413-417.
21. Xiang M., Qian Z.-Y., Zhou C.-H., Liu J., Li W.-N. Crocetin inhibits leukocyte adherence to vascular endothelial cells induced by AGEs. Journal of Ethnopharmacology 2006, 107:25-31.
22. Dai Y., Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clinical Cancer Research 2010, 16:376-383.
23. Nijhawan D., Fang M., Traer E., Zhong Q., Gao W., Du F., Wang X. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes & Development 2003, 17:1475-1486.
24. Kachhap S.K., Rosmus N., Collis S.J., Kortenhorst M.S., Wissing M.D., Hedayati M., Shabbeer S., Mendonca J., Deangelis J., Marchionni L., Lin J., Hoti N., Nortier J.W., DeWeese T.L., Hammers H., Carducci M.A. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS ONE 2010, 5:e11208.